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Clinical Performance of the BioPlex 2200 Syphilis Total & RPR
Assay at a Tertiary Medical Center with a High Rate of Syphilis
Merih T. Tesfazghi,a Neil W. Anderson,a Ann M. Gronowski,a Melanie L. Yarbrougha
aDepartment of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA
ABSTRACT Manual treponemal and nontreponemal serologic testing has histori-
cally been used for the diagnosis of syphilis. This approach is simple and reproduc-
ible but labor intensive. Recently, the FDA cleared the fully automated BioPlex 2200
Syphilis Total & RPR assay for the detection of treponemal and nontreponemal anti-
bodies. We evaluated the clinical performance of this assay at a tertiary medical cen-
ter with a high syphilis prevalence. Prospective consecutively collected (n  400)
and known RPR-positive (n  100) specimens were compared using predicate man-
ual rapid plasma reagin (RPR) and ﬂuorescent treponemal antibody absorption (FTA)
methods and the BioPlex 2200 Syphilis Total & RPR assay. Positive and negative per-
cent agreements (PPA and NPA, respectively) between the assays were calculated.
The PPA and NPA between the manual and BioPlex 2200 RPR results for the pro-
spective population were 85% (17/20; 95% conﬁdence interval [CI], 69% to 100%)
and 98% (373/380; 95% CI, 97% to 99%), respectively. The PPA for the manual RPR-
positive population was 88% (88/100; 95% CI, 82% to 94%). Overall, the manual and
BioPlex 2200 RPR titers demonstrated 78% (99/127) concordance within 1 dilution
and 94% (120/127) within 2 dilutions. An interpretation of the syphilis serologic
proﬁle using the traditional algorithm showed a concordance of 99.5% in the pro-
spective population and 85% in the manual RPR-positive cohort. The performance of
the BioPlex 2200 Syphilis Total & RPR assay is comparable to those of manual meth-
ods. The high NPA of this assay combined with the ability to automate a historically
labor-intensive assay is an appealing attribute for syphilis screening in a high-volume
laboratory.
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Syphilis, which is caused by the bacterium Treponema pallidum subspecies pallidum,is a major cause of genital ulcerative disease and other manifestations worldwide.
The sexually transmitted infection is divided into primary, secondary, or tertiary stages
that depend on clinical manifestations (1). Asymptomatic infection is known as latent
syphilis. Inadequate treatment of syphilis can lead to severe neurological and cardio-
vascular sequelae and congenital transmission to an infant from an infected mother.
Thus, timely recognition of disease is essential to prevent morbidity and further
transmission. The diagnosis of syphilis is typically made via serologic testing (2).
However, diagnosis is complicated by the wide array of disease manifestations and the
lack of a single optimal diagnostic test.
Serologic testing methods for syphilis include treponemal-speciﬁc and nontrepone-
mal tests that detect antibodies directed against host antigens released upon cell
damage (3). In the traditional algorithm for syphilis testing, screening is via a nontrepo-
nemal test, such as venereal disease research laboratory (VDRL) or rapid plasma reagin
(RPR) tests. As these tests lack speciﬁcity, positive results are conﬁrmed by a
treponemal-speciﬁc test, such as a T. pallidum enzyme immunoassay (TP-EIA), the T.
pallidum particle agglutination (TPPA), or the ﬂuorescent treponemal antibody absorp-
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tion (FTA) tests. While nontreponemal tests are useful to screen for active infection and
monitor the response to treatment, treponemal tests typically produce positive results
for life and do not distinguish between current and past infections.
The traditional screening algorithm is a cost-effective and reliable approach to
syphilis diagnosis. However, these methods are labor intensive, and the interpretation
of results for nontreponemal tests is often subjective. Due to the availability of
high-throughput automated TP-EIAs, some laboratories have instituted a reverse
screening algorithm in which initial testing consists of an automated treponemal
speciﬁc method. Positive results are followed by nontreponemal testing to distinguish
active infection. The main advantage of the reverse algorithm is that the ﬁrst step of the
screen is automated. Thus, only positive tests need to be conﬁrmed by manual
nontreponemal testing, which is appealing to high-volume laboratories. Studies have
demonstrated that this method may be useful for the detection of patients with
untreated latent syphilis in whom nontreponemal testing is negative (4, 5). However,
discordant results between treponemal and nontreponemal testing can lead to uncer-
tainty in patient management and counseling (6, 7).
The BioPlex 2200 Syphilis Total & RPR assay is a multiplex ﬂow immunoassay
intended for the simultaneous detection of nontreponemal reagin antibodies and total
(IgG/IgM) treponemal antibodies in human serum or plasma (8). The fully automated
assay employs antigen-coated ﬂuoromagnetic beads with unique ﬂuorescent signa-
tures to identify the presence of IgG or IgM antibodies to reagin antigens or T. pallidum.
Thus, this is the ﬁrst FDA-cleared assay that enables fully automated serologic testing
for syphilis. While the Syphilis Total & RPR assays are performed simultaneously, the
Syphilis Total results can be reported selectively on the basis of a positive RPR result,
enabling the use of the traditional forward algorithm for interpretation. The objective
of this study was to evaluate the diagnostic performance of this assay at a tertiary
medical center with a high rate of syphilis.
(This work was presented in part as a poster presentation at AACC, Chicago, IL, July
2018.)
MATERIALS AND METHODS
Study population. Two sample populations were utilized in this study: (i) prospective, 400 consec-
utive residual adult and pediatric serum samples sent to the Barnes-Jewish Hospital clinical laboratory for
physician-ordered syphilis screening as part of a standard of care (July to August 2017); (ii) retrospective,
100 known RPR-positive residual serum samples from pediatric and adult patients sent to the Barnes-
Jewish Hospital clinical laboratory for physician-ordered syphilis screening as part of a standard of care
between November 2016 and September 2017 (excluding the time the prospective specimens were
collected). Samples were frozen at 80°C until testing on the BioPlex 2200. No sample was frozen for
10 months. The Barnes-Jewish Hospital is a tertiary academic medical center with 1,250 beds located
in an urban environment with a high rate of syphilis (32.4 cases per 100,000 people compared to 9.2
cases per 100,000 people at a national level) (9). This study was approved by the Washington University
Human Research Protection Ofﬁce (HRPO).
Manual testing. All serum samples were tested by the predicate manual method using a traditional
screening approach. The algorithm consisted of nontreponemal testing using the Wampole Impact RPR
card test according to the manufacturer’s package insert (Alere North America, Inc., Orlando, FL) with
conﬁrmation by the Zeus IFA FTA-ABS Test system according to the manufacturer’s package insert (Zeus
Scientiﬁc, Branchburg, NJ). The titers were determined for all positive RPR samples using doubling
dilutions and were reported from 1:1 to endpoint.
BioPlex 2200 testing. After thawing at room temperature, the samples were tested with the BioPlex
2200 Syphilis Total & RPR assay (Bio-Rad Laboratories, Hercules, CA) according to the manufacturer’s
package insert (8). The BioPlex 2200 Syphilis Total & RPR assay is a multiplex ﬂow immunoassay for the
qualitative detection of IgG and IgM antibodies to Treponema pallidum (Total) and qualitative detection
with optional titer determination of nontreponemal regain antibodies (RPR). For this study, the titers
were determined for all reactive RPR samples by on-board dilution and were reported as 1:4, 1:4, 1:8,
1:16, 1:32, or 1:64. Because on-board titers reported via the BioPlex 2200 RPR assay have different start
and endpoints than the manual method, any titers at or below 1:4 and at or above 1:64 were considered
equivalent between the two methods (see Table S1 in the supplemental material).
Discordant testing. Any discrepant results between the manual and BioPlex 2200 assays (either RPR
or treponemal testing) were further evaluated using a Serodia Treponema pallidum particle-agglutination
(TPPA) assay according to the manufacturer’s package insert (Fujirebio, Malvern, PA, USA). Discrepant
samples were sent (with results blinded) to Bio-Rad for TPPA testing.
Data analysis. The performance of the BioPlex 2200 RPR assay was evaluated by calculating positive
percent agreement (PPA) and negative percent agreement (NPA) against the manual RPR method.
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Conﬁdence intervals (CIs) were calculated using the Wilson score method. The ﬁnal comparator cate-
gorical results were interpreted using the traditional algorithm, and overall concordance was calculated.
Per the traditional algorithm, positive RPR testing was followed by conﬁrmatory FTA testing. RPR
nonreactive results or RPR reactive/FTA-negative results were interpreted as negative for syphilis
infection. RPR and FTA reactive specimens were considered positive for syphilis infection.
RESULTS
Characteristics of the study populations. Prospective consecutively collected
specimens (n  400) and manual RPR-positive specimens (n  100) were used to
evaluate the performance of the BioPlex 2200 Syphilis Total & RPR assay in this study.
As shown in Table 1, the majority of the prospective population (81% [323/400]) was
18 years or older (median, 29 years; range, 0 to 85 years), and 66% (263/400) were
female, with 14% (36/263) known to be pregnant. For the prospective specimens, 7.5%
(30/400) were collected from HIV-positive subjects, of whom 87% (26/30) were male. Of
the manual RPR-positive specimens, 99 of 100 (99%) were collected from adults of
18 years or older, with a median age of 30 years (range, 18 to 79 years). In this specimen
population, 50% (8/16) of the female subjects were pregnant and 47% (47/100) were
HIV-positive individuals.
Comparison of the performance of BioPlex 2200 RPR assay with that of the
manual RPR method. The PPA and NPA for the 400 prospectively collected specimens
were 85% (17/20; 95% CI, 69% to 100%) and 98% (373/380; 95% CI, 97% to 99%),
respectively (Table 2). Of the 3 prospective specimens that were reactive with the
manual RPR but negative by the BioPlex 2200 RPR assay, one specimen was conﬁrmed
as negative by both FTA and TPPA treponemal testing, suggesting a false-positive
manual RPR result. The other two specimens were obtained from adult HIV-positive
men with low RPR titers reported by the manual method (1:4 in both cases). The
overall concordance of the RPR results in the prospective population was 97.5%
(390/400). At a subpopulation level, the PPA and NPA for HIV-positive individuals were
82% (9/11; 95% CI, 59% to 100%) and 100% (19/19; 95% CI, 100%), respectively. The PPA
and NPA for pregnant women were 0% (0/1) and 100% (35/35), respectively.
As shown in Table 3, the PPA of the manual RPR-positive population was 88%
(88/100; 95% CI, 82% to 94%). Seven of the twelve discordant results demonstrated low
positive RPR titers 1:4 by the manual RPR method. A subpopulation analysis of
HIV-positive individuals and pregnant women showed PPAs of 91% (43/47; 95% CI, 84%
to 99%) and 75% (6/8; 95% CI, 45% to 100%), respectively.
Concordance of BioPlex 2200 RPR and manual RPR titers. Positive RPR results are
routinely reported with antibody titers. Including both study populations, a total of 127
TABLE 1 Demographics of all populations categorized by sex and subcategorized by age,
pregnancy, and HIV status
Parameter
Prospective population (n  400)
Known RPR population
(n 100)
Male (n [%]) Female (n [%]) Male (n [%]) Female (n [%])
Age (yrs)
1 37 (9.2) 30 (7.5) 1 (1.0) 0 (0)
15–17 0 (0) 10 (2.5) 0 (0) 0 (0)
18 100 (25.0) 223 (55.8) 83 (83.0) 16 (16.0)
Pregnancy
Positive 36 (13.7) 8 (50.0)
Negative 166 (63.1) 4 (25.0)
Unknown 61 (23.2) 4 (25.0)
HIV
Positive 26 (6.5) 4 (1.0) 45 (45.0) 2 (2.0)
Negative 59 (14.8) 210 (52.5) 36 (36.0) 12 (12.0)
Unknown 52 (12.2) 49 (12.2) 3 (3.0) 2 (2.0)
Total 137 (34.0) 263 (66.0) 84 (84.0) 16 (16.0)
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specimens were RPR positive by one or both assays. Of the titers reported on these
specimens, 99 of 127 (78%) results were concordant within 1 doubling dilution and
120 of 127 (94%) within 2 doubling dilutions (Table 4). The majority of RPR titers
reported from positive specimens using the manual method (53%) or the BioPlex 2200
RPR assay (60%) demonstrated titers 1:4 (Fig. 1).
Concordance of syphilis algorithm interpretation. Using the traditional algorithm
to interpret syphilis serologic testing results, the status of syphilis infection was
categorized for each population. In the prospective population, 381 of 400 specimens
were interpreted as negative for active syphilis infection, of which 373 were RPR
nonreactive by both methods, 7 were manual RPR nonreactive and BioPlex 2200 RPR
TABLE 2 Agreement between the manual RPR and BioPlex 2200 RPR results from 400
prospectively collected specimens
Specimen source
RPR result (n)
PPAa (95% CI) NPAb (95% CI)BioPlex 2200
Manualc
R NR Total
All R 17 7d 24 85 (69–100) 98 (97–99)
NR 3e 373 376
Total 20 380 400
HIV positive R 9 0 9 82 (59–100) 100
NR 2 19 21
Total 11 19 30
Pregnant R 0 0 0 0 100
NR 1 35 36
Total 1 35 36
Infant R 0 1 1 99 (96–100)
NR 0 66 66
Total 0 67 67
aPPA, positive percent agreement.
bNPA, negative percent agreement.
cR, reactive; NR, nonreactive.
dBioPlex RPR titers were 1:4 for 7 discordant specimens. TPPA testing was nonreactive in all samples.
eManual RPR titers were 1:4 for 3 discordant samples. TPPA testing was negative for 1/3 samples.
TABLE 3 Agreement between the manual RPR and BioPlex 2200 RPR results from 100
known RPR-positive specimens
Specimen source
RPR result (n)
PPAa (95% CI)BioPlex 2200
Manualb
R NR Total
Known RPR population R 88 0 88 88 (82–94)
NR 12c 0 12
Total 100 0 100
HIV positive R 43 0 43 91 (84–99)
NR 4 0 4
Total 47 0 47
Pregnant R 6 0 6 75 (45–100)
NR 2 0 2
Total 8 0 8
Infant R 1 0 1 100
NR 0 0 0
Total 1 0 1
aPPA, positive percent agreement.
bR, reactive; NR, nonreactive.
cFor 12 discordant results, 11 had titers 1:4 and one had a titer of 1:8. TPPA testing was reactive for 10/12
discordant results.
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reactive followed by negative BioPlex 2200 Syphilis Total results, and one specimen that
was manual RPR reactive followed by FTA negative that was BioPlex 2200 RPR nonre-
active. Seventeen of four hundred specimens were interpreted as positive by both
methods (RPR reactive followed by positive FTA and BioPlex 2200 Syphilis Total results)
(Table 5). Two specimens characterized as active syphilis by manual methods (RPR and FTA
reactive) were interpreted as negative by the BioPlex 2200 RPR assay. Both specimens
tested positive by TPPA. The overall concordance of test interpretation between the BioPlex
2200 andmanual methods was 99.5% (398/400). An analysis of these data using the reverse
algorithm for result interpretation in the prospectively collected specimens revealed that 17
of 400 (4.3%) specimens would have screened positive by the BioPlex 2200 Syphilis Total
assay but negative by the BioPlex 2200 RPR assay.
In the known RPR-positive population, 14 specimens that were interpreted by the
traditional algorithm as active syphilis by the manual method (RPR positive, FTA
positive) tested negative for syphilis infection by the BioPlex 2200 assay (12 were
nonreactive by RPR and 2 were RPR reactive but Syphilis Total negative). Notably, 4 of
the 14 positive specimens tested negative by a third TPPA method, indicating that
these were likely falsely reactive by the manual method. One specimen that was
negative by the manual method (RPR positive but FTA nonreactive) demonstrated
positive RPR and Syphilis Total results on the BioPlex 2200 (Table 5). TPPA testing was
nonreactive for this specimen, indicating agreement with the manual method. Thus,
the overall concordance of test interpretation in the manual RPR-positive population
was 85% (85/100). If the results of discrepant analyses are taken into consideration, the
concordance of this population was 89% (89/100).
DISCUSSION
Here, we report the clinical performance of the BioPlex 2200 Syphilis Total & RPR
assay at an urban tertiary medical center with a high volume of syphilis testing. To our
knowledge, this is the ﬁrst evaluation of the recently FDA-cleared BioPlex 2200 Syphilis
TABLE 4 Concordance of BioPlex 2200 RPR titer with the manual RPR titer resulta
Titer variation from manual
RPR (no. of dilutions) No. of results
% concordance
1 dilution 2 dilutions
2 4
2 15
 or 1 99 78 (99/127) 94 (120/127)
2 6
2 3
aResults for 127 specimens with RPR-positive result by either method: 27 from the prospective population,
and 100 from the known RPR-positive population.
FIG 1 Distribution of RPR titers via manual and BioPlex 2200 methods obtained from RPR-positive
specimens.
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Total & RPR assay. Because of the manual nature of RPR assays, which are the ﬁrst step
of the traditional forward algorithm, many laboratories have transitioned to a reverse
algorithm, in which the ﬁrst step consists of testing with a treponemal EIA that is
amenable to automation (10–12). This enables an increased throughput in laboratories
with a high volume of testing.
With the reverse algorithm, laboratories eliminate the need for manual RPR testing
in any specimen with a negative treponemal screen. However, the frequent occurrence
of discordant results (positive treponemal screening tests with a negative RPR) may
lead to clinical uncertainty. In such cases, the CDC recommends additional treponemal
testing by a second assay to help resolve discrepancies (13). However, because this
“tiebreaker” test is a treponemal assay, it suffers from similar limitations to the original
screening test, making past or present syphilis hard to differentiate. Prior studies have
noted signiﬁcantly more positive screens using the reverse algorithm in a low-
prevalence population (4, 14). This effect is ampliﬁed in a high-prevalence population
such as our cohort. In fact, the use of the reverse algorithm to interpret the data in the
prospective cohort would have necessitated a third test method in 4% of specimens
that tested positive by the BioPlex 2200 Syphilis Total assay but negative by BioPlex
2200 RPR assay. To reduce the need for additional conﬁrmatory testing in laboratories
using the reverse algorithm, several studies have attempted to correlate the signal
strength of a positive treponemal test to predict a reactive conﬁrmatory test result (15,
16). The use of the traditional algorithm would preclude the need for establishing signal
strength cutoffs or for performing extra conﬁrmatory testing.
The BioPlex 2200 Syphilis Total & RPR assay enables full automation of both the
screen and conﬁrmatory tests on a single instrument. This facilitates the interpretation
of test results using the traditional algorithm and avoids the confusion of the reverse
algorithm by performing the nontreponemal assay ﬁrst. This is particularly advanta-
geous for laboratories in areas with high rates of syphilis in which background
seropositivity is high. A potential pitfall of this assay is the potential for a higher cost
than that of the manual method. Although further investigation is required to deﬁni-
tively ascertain the cost beneﬁt, potential additional costs may be offset by decreased
hands-on time in the laboratory and through downstream effects in patient care from
faster results and less need for follow-up testing. Additional beneﬁts of the BioPlex 2200
Syphilis Total & RPR assay include higher throughput, interface with laboratory infor-
mation systems, decreased opportunity for manual errors, result standardization, im-
mediate availability of conﬁrmatory testing after a positive RPR, and automated dilu-
tions for titers.
The performance of the BioPlex 2200 RPR assay was comparable to that of the
manual method, with overall PPA and NPA of 85% and 98%, respectively, in the
prospective population. Follow-up discrepant testing was negative for one specimen,
suggesting a false-positive manual RPR result. The other two discrepant specimens
TABLE 5 Concordance of syphilis interpretation using traditional algorithm for the
prospective and known RPR positive populations
Population
Result (n)
% concordanceBioPlex 2200
Manuala
RPR RPR FTAb RPR FTA
Prospective (n  400) RPR 373 1 2 99.5 (398/400)
RPR STc 7 0 0
RPR ST 0 0 17
Known RPR (n  100) RPR 0 12 85 (85/100)
RPR ST 0 2
RPR ST 1 85
aShading indicates discordant results when interpreted using forward algorithm, i.e., treponemal assay
performed only if RPR positive.
bFTA, ﬂuorescent treponemal antibody absorption.
cST, syphilis total.
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were obtained from adult HIV-positive males with low RPR titers (1:4), and both
specimens were positive by manual FTA and BioPlex 2200 Syphilis Total methods. While
no additional clinical information was available to arbitrate these discrepancies, these
results may suggest a recent history of treated syphilis or the possibility that an
attenuated immune response hampered the detection by the BioPlex 2200 assay in
these specimens.
We observed excellent overall concordance of the interpretation of the serologic proﬁle
using the traditional algorithm in the prospective population. In the manual RPR-positive
population, the concordance of the syphilis serologic interpretation dropped to 85%,
mostly due to 12 specimens that tested negative for RPR on the BioPlex 2200 assay and two
that were negative on the BioPlex 2200 Syphilis Total but positive by FTA. The decreased
concordance in this population is likely an effect of selection bias, as the analyzed popu-
lation consisted only of manual RPR-positive patients and is not representative of the
population intended to be analyzed by this method. While we lack clinical data to aid the
interpretation of these results, 4 of the 14 specimens tested negative by the second
treponemal TPPA method, suggesting the possibility of false-positive results by the more
subjective and less speciﬁc manual RPR and FTA methods.
Positive RPR results are typically reported in conjunction with titers, which are used
clinically to monitor therapeutic response (17). The BioPlex 2200 RPR assay is capable of
performing onboard dilutions for optional titer determination. Due to the inherent vari-
ability of titer determination, we considered any BioPlex 2200 RPR result within one dilution
of the manual result concordant. Good concordance (78%) of the BioPlex 2200 RPR assay
was observedwith the predicatemanual method. Discordant results weremostly attributed
to titer results of1:4 on the BioPlex 2200 RPR assay in specimens with titers of 1:8 or 1:16
determined by the manual method. Notably, more than 94% of the reported titers were
within two dilutions between the manual and BioPlex 2200 RPR methods.
One limitation of this study is that the specimens were obtained with limited clinical
data. Thus, we were not able to clinically stage syphilis into primary, secondary, latent,
and tertiary infections. Second, due to lack of adequate clinical information, it is difﬁcult
to arbitrate discordant results, even after a discrepant analysis was performed by a third
treponemal assay (TPPA). Third, this study was performed at a single large tertiary
medical center with a high syphilis prevalence. Further investigation may be needed to
evaluate the clinical performance of BioPlex 2200 Syphilis Total & RPR assay in areas
with low syphilis prevalence. Lastly, BioPlex 2200 RPR titers were reported on the
instrument at a maximum dilution of 1:64. Thus, we are unable to assess the accuracy
of this method at higher titers. For clinicians following titers as a measure of a response
to therapy, onboard determination of higher RPR titers with a prior ofﬂine dilution step
is now supported on the BioPlex 2200. However, this feature was not assessed in our
study. A major advantage of this study is that a large number of well-preserved clinical
specimens, including 100 manual RPR-positive specimens, were evaluated, which en-
abled the assessment of all aspects of syphilis diagnostic testing, from nontreponemal
and treponemal assays to serologic interpretation.
This study, for the ﬁrst time, establishes the clinical performance of a recently
FDA-cleared automated BioPlex 2200 Syphilis Total & RPR assay at a tertiary medical
center with a high rate of syphilis infection. The performance of the BioPlex 2200
Syphilis Total & RPR assay was comparable to those of the manual RPR and FTA
methods. While the sensitivity of the BioPlex 2200 RPR method may be lower than that
of traditional manual RPR assays, the ability to interpret the results using the traditional
algorithm is a major beneﬁt of this method. The high NPA of this assay, in combination
with the ability to automate a historically labor-intensive method, make it well suited
for use as a diagnostic testing modality for syphilis in a high-volume laboratory.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/JCM
.01487-18.
SUPPLEMENTAL FILE 1, PDF ﬁle, 0.2 MB.
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